Neuralstem Inc

Find Ratings Reports
CUR : NASDAQ : Health Care
$0.32 | %
Today's Range: 0.31 - 0.32
Avg. Daily Volume: 766,900
09/23/16 - 4:00 PM ET

Financial Analysis


NEURALSTEM INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. NEURALSTEM INC has average liquidity. Currently, the Quick Ratio is 1.29 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 94.24% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)0.00.0
EBITDA ($mil)-3.74-4.91
EBIT ($mil)-3.84-5.0
Net Income ($mil)-3.85-5.45


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)11.1323.68
Total Assets ($mil)13.326.37
Total Debt ($mil)5.918.98
Equity ($mil)0.8414.54


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin-187150.0-245600.0
EBITDA Margin-187150.0-245600.0
Operating Margin-191750.0-249750.0
Sales Turnover0.00.0
Return on Assets-156.9-77.58
Return on Equity-2495.33-140.72
Debt Q2 FY16 Q2 FY15
Current Ratio1.374.18
Debt/Capital0.880.38
Interest Expense0.320.46
Interest Coverage-11.91-10.88


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)114.7690.36
Div / share0.00.0
EPS-0.04-0.06
Book value / share0.010.16
Institutional Own % n/a n/a
Avg Daily Volume724742.0481207.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 38.89 indicates a significant premium versus the S&P 500 average of 2.78 and a significant premium versus the industry average of 10.46. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, NEURALSTEM INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CUR NM Peers 42.78   CUR NM Peers 21.27

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CUR's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CUR's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CUR NM Peers 31.52   CUR NA Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

CUR's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CUR 38.89 Peers 10.46   CUR 4.35 Peers 1.93

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CUR is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CUR is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CUR 3213.31 Peers 690.55   CUR -33.34 Peers 51.56

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CUR is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CUR significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades